10 research outputs found

    A Measurement of the Decay Asymmetry Parameters in \Xi_{c}^{0}\to \X^{-}\pi^{+}

    Full text link
    Using the CLEO II detector at the Cornell Electron Storage Ring we have measured the Ξc0\Xi_c^{0} decay asymmetry parameter in the decay Ξc0→Ξ−π+\Xi_c^{0} \to \Xi^{-} \pi^+. We find αΞc0αΞ=0.26±0.18(stat)−0.04+0.05(syst)\alpha_{\Xi_c^{0}} \alpha_{\Xi} = 0.26 \pm 0.18{(stat)}^{+0.05}_{-0.04}{(syst)}, using the world average value of αΞ=−0.456±0.014\alpha_{\Xi} = -0.456 \pm 0.014 we obtain αΞc0=−0.56±0.39(stat)−0.09+0.10(syst)\alpha_{\Xi_c^{0}} = -0.56 \pm 0.39{(stat)}^{+0.10}_{-0.09}{(syst)}. The physically allowed range of a decay asymmetry parameter is −1<α<+1-1<\alpha<+1. Our result prefers a negative value: αΞc0\alpha_{\Xi_c^{0}} is <0.1<0.1 at the 90% CL. The central value occupies the middle of the theoretically expected range but is not yet precise enough to choose between models.Comment: 10 pages postscript, also available through http://w4.lns.cornell.edu/public/CLN

    Autoantibodies against type I IFNs in patients with life-threatening COVID-19

    Get PDF
    Interindividual clinical variability in the course of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is vast. We report that at least 101 of 987 patients with life-threatening coronavirus disease 2019 (COVID-19) pneumonia had neutralizing immunoglobulin G (IgG) autoantibodies (auto-Abs) against interferon-w (IFN-w) (13 patients), against the 13 types of IFN-a (36), or against both (52) at the onset of critical disease; a few also had auto-Abs against the other three type I IFNs. The auto-Abs neutralize the ability of the corresponding type I IFNs to block SARS-CoV-2 infection in vitro. These auto-Abs were not found in 663 individuals with asymptomatic or mild SARS-CoV-2 infection and were present in only 4 of 1227 healthy individuals. Patients with auto-Abs were aged 25 to 87 years and 95 of the 101 were men. A B cell autoimmune phenocopy of inborn errors of type I IFN immunity accounts for life-threatening COVID-19 pneumonia in at least 2.6% of women and 12.5% of men

    Recent Progress in the Development of Small Molecule c-Met Inhibitors

    No full text

    Lasers

    No full text

    Computer-Aided Drug Design Applied to Secondary Metabolites as Anticancer Agents

    No full text
    corecore